Silence Therapeutics PLC Sponsored ADR

SLN Healthcare Biotechnology

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.

8.68 0.67 −7.17%
Market cap
$581.1M
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
2/9
Altman Z
−4.82
Beneish M
45.78
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
48.17 78.72 43.33 58.42 50.00 101.12 88.00 68.79 147.33 85.11
Receivables
3.35 3.59 3.99 6.13 42.17 10.01 19.54 22.73 25.37 22.01
Other current assets
0.35 0.95 0.84 0.75 5.93 7.59 12.05 11.63 14.66 11.54
Total current assets
51.87 83.26 48.17 65.31 98.10 118.72 119.59 103.15 187.37 118.66
Property, Plant, Equpment (Net)
1.70 2.14 1.50 1.07 1.45 2.67 2.72 1.94 1.82 1.58
Long-Term Investments
5.45 — 0.45 0.48 0.39 0.41 0.35 — — —
Goodwill and Intangible Assets (Total)
9.57 14.73 13.37 13.47 10.45 10.47 10.30 10.34 9.70 10.91
Long-term assets (Other)
— — — — — — — 3.65 3.59 0.13
Total non-current assets
— — — — 12.29 13.56 13.38 16.30 15.27 12.78
Total Assets
68.88 — 63.49 — 110.39 132.28 132.97 119.45 202.64 131.44
Accounts Payable
0.65 0.84 1.87 3.12 10.52 14.83 15.63 15.54 16.40 13.36
Current Part of Capital Lease
— — — — 0.44 0.19 0.55 0.22 — —
Other current liabilities
1.34 4.01 4.34 13.21 21.88 5.84 10.96 6.57 0.31 0.17
Total current liabilities
1.99 4.86 6.25 16.83 32.84 20.86 27.14 22.34 16.82 13.61
Non-current Liabilities (Other)
— — — 0.00 65.92 99.70 78.52 75.00 51.79 55.45
Total non-current liabilities
— — — — 65.92 99.70 78.52 75.12 51.79 55.53
Total liabilities
1.99 4.86 6.25 43.87 98.76 120.55 105.67 97.46 68.61 69.14
Additional Paid In Capital
— — — — 239.97 310.03 343.69 455.77 609.56 617.56
Common Stock (Net)
4.31 6.40 5.80 6.83 5.35 6.17 6.67 8.85 10.29 10.29
Retained Earnings
(115.68) (212.84) (218.43) (226.17) (236.53) (306.60) (325.63) (431.89) (474.04) (562.57)
Shareholders Equity (Other)
— — — — 2.85 2.12 2.58 2.43 — —
Common Equity (Total)
66.89 95.70 57.24 36.45 11.63 11.72 27.30 21.99 134.02 62.30
Shareholders Equity (Total)
66.89 95.70 57.24 36.45 11.63 11.72 27.30 21.99 134.02 62.30
Shareholders Equity and Liabilities (Total)
— — — — 110.39 132.28 132.97 119.45 202.64 131.44
Shares (Common)
— — — — 27.77 29.93 35.94 39.62 47.23 47.23
Shareholders Equity (Tangible)
— — — — 1.18 1.25 17.00 11.65 124.32 51.40
Net Debt
(48.17) (78.72) (43.33) (58.42) (50.00) (101.12) (88.00) (68.79) (147.33) (85.11)
Total Debt
— — — 0.50 0.64 0.25 0.65 0.12 — —

Fold the line items

In millions of $ except per-share values · columns are period end dates